Company profile: Fulcrum Therapeutics
1.1 - Company Overview
Company description
- Provider of biotechnology therapies targeting rare genetic diseases at their root cause, including losmapimod (a small molecule under investigation for facioscapulohumeral muscular dystrophy) and FTX-6058 (a small molecule designed to increase expression of fetal hemoglobin for treating sickle cell disease and beta-thalassemia).
Products and services
- FTX-6058: An engineered small molecule that increases fetal hemoglobin expression for treating sickle cell disease and beta-thalassemia, enabling pharmacologic HbF induction as a therapeutic approach
- Losmapimod: An investigational small molecule under evaluation for the treatment of facioscapulohumeral muscular dystrophy (FSHD), being tested as a pharmacologic therapy candidate for FSHD
- Root-Cause Rare Genetic Disease Research: A mechanism-focused capability that identifies and treats rare genetic diseases at their root cause, concentrating efforts on causal genetic mechanisms
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Fulcrum Therapeutics
Iridia
HQ: United States
Website
- Description: Provider of nanotechnology solutions that embed synthetic DNA molecules into products to deliver authenticity, traceability, and data infusion. Offers a Molecular Avatar Technology platform for supply chain transparency, embedding data directly into materials, enabling personalized information and Web3-enabled utilities for enhanced customer engagement, and art authentication to ensure provenance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iridia company profile →
Biomodal
HQ: United Kingdom
Website
- Description: Provider of DNA sequencing tools and multiomic solutions enabling combined genetic and epigenetic analysis from low-input DNA, distinguishing 5mC and 5hmC via duet multiomics solution evoC and +modC, which integrates assay and software for use with existing NGS pipelines; and modality, an analysis package for efficient, scalable 5- and 6-base genome analysis to inform genome organization and gene regulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomodal company profile →
Lysogene
HQ: France
Website
- Description: Provider of basic research and clinical development of gene therapy for neurodegenerative disorders, developing AAV vectors, with a mission to improve the health of patients with incurable, life-threatening conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lysogene company profile →
Cygnus Technologies
HQ: United States
Website
- Description: Provider of generic kits, immunoassay reagents, and antibody and assay development services to pharmaceutical and biotechnology industries. Specializes in custom antibody and assay development for host cell protein detection in recombinant pharmaceuticals and supplies specialized analytical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cygnus Technologies company profile →
OPX Biotechnologies
HQ: United States
Website
- Description: Provider of bioengineering technology to convert renewable feedstocks into biofuels and green chemistry products, leveraging its proprietary OPX EDGE (Efficiency Directed Genome Engineering) platform for rapid, rational, and robust optimization of microbes and bioprocesses; Colorado-based.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OPX Biotechnologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Fulcrum Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Fulcrum Therapeutics
2.2 - Growth funds investing in similar companies to Fulcrum Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Fulcrum Therapeutics
4.2 - Public trading comparable groups for Fulcrum Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →